Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
NCT ID: NCT00373711
Last Updated: 2022-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
NCT01374659
Thyroid Cancer and (FDG)PET/CT Scan
NCT04128631
Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer
NCT03196518
Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
NCT05175404
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
NCT02856347
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iodine-124
2 mCi, oral
Iodine-123
2 mCi, oral
F-18 FDG
10-15 mCi, iv
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Detectable levels of Tg.
* Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
* Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
* Patients older than 18-year-old.
* Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
* Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.
Exclusion Criteria
* Pregnant women.
* Healthy volunteers.
* Patients participating in other research studies.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stanford University School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrei Iagaru
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Iain Ross McDougall
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
97454
Identifier Type: OTHER
Identifier Source: secondary_id
END0003
Identifier Type: OTHER
Identifier Source: secondary_id
END0003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.